MAP2K2 and neoplasm: MAP2K2-KO in tumor cells also results in significant overexpression of the immune checkpoint receptor ligand PDCD1LG2 (LFC: 0.2, Q: 0.01) and downregulation of the marker of cytotoxicity GNLY (LFC: −0.29, Q: 0.03).